Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

calbucs Jul. 28 at 8:38 PM

$NKTR they don’t have to prove malicious intend , their error which they admitted to cost them millions !! We will see how it works out but big Pharma preying on the little guy to push their own agenda does not look good .

1 · Reply

george4it Jul. 28 at 8:18 PM

$NKTR AccumulAtion continues. Added a few more at 23.7.

0 · Reply

Edenlaor Jul. 28 at 7:55 PM

$NKTR @breakoutstock where are you to save this???

1 · Reply

AnAverageDude Jul. 28 at 3:48 PM

$NKTR long story short the drug failed phase 2 for lupus, there is no denying this. This was also apart of the deal. Lilly had every right to back out. Good luck proving malicious intent. No settlement coming.

2 · Reply

RinseX3 Jul. 25 at 4:28 PM

$NKTR Let the traders trade and the institutions move shares from one hand to the other. What is almost certain is that any day during the next 2-3 months we may wake up to a very significant partnership deal multiples above the current market cap. A big part of successful investing is just sitting on your hands and waiting for opportunities to materialize.

1 · Reply

calbucs Jul. 25 at 12:52 PM

$NKTR BOT BLOCKED ! DA

0 · Reply

Gros_gerrard Jul. 24 at 3:25 PM

$NKTR nktrash ....

1 · Reply

BK217 Jul. 24 at 2:18 AM

$NKTR the mark of the beast

0 · Reply

FesertBoy Jul. 24 at 12:52 AM

$NKTR volume today was the guys from X that made a ton on abvx buying more this morning.

0 · Reply

Suckits4 Jul. 23 at 6:35 PM

$NKTR any capital raises coming here soon?

1 · Reply

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 1, 2025, 7:17 AM EDT - 27 days ago

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Jun 30, 2025, 4:02 PM EDT - 4 weeks ago

Nektar Therapeutics Announces Proposed Public Offering

Jun 27, 2025, 8:45 AM EDT - 4 weeks ago

Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg

Jun 25, 2025, 1:42 PM EDT - 4 weeks ago

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

Jun 24, 2025, 1:20 PM EDT - 4 weeks ago

Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?

Jun 24, 2025, 7:35 AM EDT - 4 weeks ago

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Jun 24, 2025, 7:30 AM EDT - 4 weeks ago

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

Jun 23, 2025, 4:30 PM EDT - 5 weeks ago

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

Jun 11, 2025, 3:13 PM EDT - 6 weeks ago

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

Jun 10, 2025, 5:26 PM EDT - 6 weeks ago

AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance

May 13, 2025, 5:00 PM EDT - 2 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 10:08 PM EDT - 2 months ago

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:15 PM EDT - 2 months ago

Nektar Therapeutics Reports First Quarter 2025 Financial Results

May 1, 2025, 6:00 PM EDT - 3 months ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Mar 20, 2025, 6:00 PM EDT - 4 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 8:00 PM EDT - 4 months ago

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:15 PM EDT - 4 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 6:00 PM EST - 5 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Feb 26, 2025, 7:00 AM EST - 5 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Feb 24, 2025, 7:00 AM EST - 5 months ago

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Feb 24, 2025, 7:00 AM EST - 5 months ago

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Feb 10, 2025, 7:00 AM EST - 6 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Jan 10, 2025, 7:00 AM EST - 7 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

$Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting$

Dec 7, 2024, 12:00 PM EST - 8 months ago

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Nov 18, 2024, 3:30 PM EST - 9 months ago

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Nov 14, 2024, 9:11 AM EST - 9 months ago

Multiple Catalysts Ahead For Nektar Therapeutics

Nov 8, 2024, 12:21 AM EST - 9 months ago

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:15 PM EST - 9 months ago

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 10:15 AM EST - 9 months ago

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 6, 2024, 6:00 PM EST - 9 months ago

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Nov 4, 2024, 1:44 PM EST - 9 months ago

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Nov 4, 2024, 8:30 AM EST - 9 months ago

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Oct 31, 2024, 6:00 PM EDT - 9 months ago

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Oct 29, 2024, 9:00 AM EDT - 9 months ago

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

Oct 17, 2024, 12:07 PM EDT - 10 months ago

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Sep 25, 2024, 3:30 AM EDT - 10 months ago

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

Sep 3, 2024, 9:00 AM EDT - 11 months ago

Nektar Management to Present at Upcoming Investor Conferences

Aug 10, 2024, 9:04 AM EDT - 1 year ago

Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:15 PM EDT - 1 year ago

Nektar Therapeutics Reports Second Quarter 2024 Financial Results

Aug 1, 2024, 6:00 PM EDT - 1 year ago

Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets

Jun 12, 2024, 9:30 AM EDT - 1 year ago

Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

May 9, 2024, 10:40 PM EDT - 1 year ago

Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:15 PM EDT - 1 year ago

Nektar Therapeutics Reports First Quarter 2024 Financial Results

May 2, 2024, 6:00 PM EDT - 1 year ago

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases

Mar 22, 2024, 2:00 PM EDT - 1 year ago

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 5, 2024, 9:00 AM EST - 1 year ago

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Mar 4, 2024, 10:54 PM EST - 1 year ago

Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript

Mar 4, 2024, 4:15 PM EST - 1 year ago

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

calbucs Jul. 28 at 8:38 PM

1 · Reply

george4it Jul. 28 at 8:18 PM

$NKTR AccumulAtion continues. Added a few more at 23.7.

0 · Reply

Edenlaor Jul. 28 at 7:55 PM

$NKTR @breakoutstock where are you to save this???

1 · Reply

AnAverageDude Jul. 28 at 3:48 PM

2 · Reply

RinseX3 Jul. 25 at 4:28 PM

1 · Reply

calbucs Jul. 25 at 12:52 PM

$NKTR BOT BLOCKED ! DA

0 · Reply

Gros_gerrard Jul. 24 at 3:25 PM

$NKTR nktrash ....

1 · Reply

BK217 Jul. 24 at 2:18 AM

$NKTR the mark of the beast

0 · Reply

FesertBoy Jul. 24 at 12:52 AM

$NKTR volume today was the guys from X that made a ton on abvx buying more this morning.

0 · Reply

Suckits4 Jul. 23 at 6:35 PM

$NKTR any capital raises coming here soon?

1 · Reply

breakoutstock Jul. 23 at 5:33 PM

$NKTR settlement will double the market cap according to AI.

0 · Reply

calbucs Jul. 23 at 5:10 PM

$NKTR Desperate move by LLY ! Settlement seems likely outcome sooner than later .

0 · Reply

US_Bull Jul. 23 at 1:43 PM

$NKTR Tons of volume right out of the gate. I saw on the docket that LLY has submitted a Daubert motion a desperate move IMO to try and invalidate our expert testimony from our experts. Are they running out of good arguments we are gonna find out soon.

0 · Reply

MicheleLeija706 Jul. 23 at 6:52 AM

$NKTR Letting trade behavior remain process bound

0 · Reply

UnoffensiveName Jul. 22 at 4:45 PM

$NKTR jesus...lets everyone keep an eye on this guy

1 · Reply

US_Bull Jul. 22 at 2:09 PM

$NKTR Everyday same script red on very low volume followed by green walkup just a matter of time until shorts can no longer do it and this explodes tik tok LLY when do you settle or do you wait until October for the jury trial with the uncertainty.

0 · Reply

fantastex Jul. 21 at 11:29 PM

$NKTR seems he wants to go again around 22 or 21ish..

0 · Reply

WiseGuyInvestin Jul. 21 at 9:11 PM

$NKTR 🚨🚨🚨STIPULATION AND PROPOSED ORDER SUBMITTED TODAY!!!! 🚨🚨🚨 https://www.courtlistener.com/docket/67670334/nektar-therapeutics-v-eli-lilly-co/

2 · Reply

fantastex Jul. 20 at 6:36 PM

$NKTR Who else doesn't like how this closed on Friday?

2 · Reply

nesanmano Jul. 20 at 2:34 PM

$NKTR Finra and the cse are both doing anything

0 · Reply

nesanmano Jul. 20 at 2:33 PM

$NKTR USA is fucked up. The stock market is manipulated by nasty and greedy jerks. Nuke missile is the solution

1 · Reply

AnAverageDude Jul. 19 at 4:18 PM

$LLY $NKTR this article is so old and Howard is a known liar just zoom out the chart.

1 · Reply

Market Cap	310.18M
Revenue (ttm)	98.43M
Net Income (ttm)	-118.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-120.86%
Debt to Equity Ratio	0.00

Volume	639,745
Avg Vol	2,190,278
Day's Range	N/A - N/A
Shares Out	12.41M
Stochastic %K	42%
Beta	0.94
Analysts	Strong Sell
Price Target	$94.83